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ABSTRACT   
Glycogen storage disease type 1a (GSD1a) is a rare disease due to the deficiency in the 
glucose-6-phosphatase catalytic subunit (encoded by G6pc), which is essential for 
endogenous glucose production.  Despite strict diet control to maintain blood glucose, patients 
with GSD1a develop hepatomegaly, steatosis and then hepatocellular adenomas (HCA), 
which can undergo malignant transformation. Recently, gene therapy has attracted attention as 
a potential treatment for GSD1a. In order to maintain long-term transgene expression, we 
developed an HIV-based vector, which allowed us to specifically express the human G6PC 
cDNA in the liver. We analysed the efficiency of this lentiviral vector in the prevention of the 
development of the hepatic disease in an original GSD1a mouse model, which exhibits 
G6Pase deficiency exclusively in the liver (L-G6pc-/- mice). Recombinant lentivirus were 
injected in B6.G6pcex3lox/ex3lox.SAcreERT2/w neonates and G6pc deletion was induced by 
tamoxifen treatment at weaning.  Magnetic resonance imaging was then performed to follow 
up the development of hepatic tumours. Lentiviral gene therapy restored glucose-6 
phosphatase activity sufficient to correct fasting hypoglycaemia during 9 months. Moreover, 
lentivirus-treated L-G6pc-/- mice presented normal hepatic triglyceride levels, whereas 
untreated mice developed steatosis. Glycogen stores were also decreased although liver 
weight remained high. Interestingly, lentivirus-treated L-G6pc-/- mice were protected against 
the development of hepatic tumours after 9 months of gene therapy while most of untreated L-
G6pc-/- mice developed millimetric HCA. Thus the treatment of new-borns by recombinant 
lentivirus appears as an attractive approach to protect the liver from the development of 
steatosis and hepatic tumours associated to GSD1a pathology. 
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Glycogen storage disease (GSD) type 1 is an inherited disease caused by the deficiency in 
glucose-6-phosphatase (G6Pase) activity (1–3). G6Pase catalyses the hydrolysis of glucose-6-
phosphate (G6P) into glucose and inorganic phosphate, the terminal reaction in hepatic 
glucose production, common to glycogenolysis and gluconeogenesis. GSD type 1a (GSD1a, 
OMIM #232200) is caused by mutations affecting the catalytic subunit (G6PC) (4, 5) of 
G6Pase. G6PC is specifically expressed in the liver, kidneys and intestine, which are the only 
organs capable of producing glucose in the blood (6–8). Thus patients affected by GSD1a are 
unable to produce glucose, leading to severe hypoglycaemia during fasting in association with 
lactic acidemia, hypertriglyceridemia, hyperuricemia and hypercholesterolemia (2, 3, 9). 
Furthermore, G6Pase deficiency leads to the accumulation of G6P, glycogen and triglycerides 
in the liver, resulting in hepatomegaly and steatosis. The long-term complications in hepatic 
G6Pase deficiency include focal nodular hyperplasia and, more often, hepatocellular adenoma 
(HCA), with a risk of transformation into hepatocellular carcinomas (HCC) (9–11). HCAs 
predominantly develop during and after puberty, and more than 70% of adult GSD1 patients 
have multiple HCAs. In addition, patients with GSD1a also present nephropathy and intestinal 
disorders, which appear with time (3, 9).  
The current treatment of GSD1a focuses on the prevention of hypoglycaemia and 
lactic acidemia through frequent meals and ingestion of uncooked cornstarch during the day, 
complemented by nasogastric drip-feeding of glucose or ingestion of uncooked cornstarch 
during the night (12). However, the underlying pathology remains uncorrected and the dietary 
therapy fails to prevent serious long-term complications, such as hepatic tumours. Thus 
tumour resection or liver transplantation are recommended if the tumours are associated with 
serious compression or haemorrhage, or show signs of malignant transformation into HCC 
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(12, 13). Recently, gene therapy has attracted attention as a potential treatment for GSD1a, 
since the liver is well suited for gene transfer. Indeed, the liver has been the target for in vivo 
gene therapy in many inherited metabolic diseases (14). During the last decade, several 
approaches of gene delivery have been evaluated in genetically engineered total G6pc-/- mice 
(15) and dog colonies carrying a naturally occurring G6pc mutation (16). Both of these 
models are characterized by a very short life expectancy and death by hypoglycaemia in the 
absence of nutritional or gene therapy. Most studies done on these models were performed 
using recombinant adenovirus or adeno-associated virus (AAV). AAV-mediated therapy 
performed in neonates permitted a significant correction of G6Pase activity in the liver, which 
markedly prolonged survival, corrected hypoglycaemia during fasting and improved the 
biochemical parameters (see review (17, 18)). However, the hepatomegaly was only partially 
corrected on a long term, even if no HCA was detected in one study relating to AAV-treated 
total G6pc-/- mice after 90 weeks (19). In addition, the success of AAV-based gene therapy for 
GSD1a is limited by a gradual loss of the transgene expression from episomal AAV vector 
genomes, which necessitated a re-administration of a different pseudotype of the AAV vector 
to sustain animals with total deficiency of G6Pase only few months after the first one (17, 20, 
21). To overcome some of the limitations of AAV gene therapy, we developed a new gene 
delivery approach able to maintain the transgene over time, based on the use of an HIV-1-
based lentiviral vector. Lentiviral vectors efficiently integrate into the host genome, providing 
stable long-term expression of the transgene even in cells that are actively dividing (22), and 
are not associated with insertional mutagenesis in the liver (23–26). The efficiency of 
lentiviral-mediated therapy has been validated in several animal models of inherited liver 
diseases, such as Crigler-Najjar type 1, Wilson disease and hemophilia (27–31). 
In the present work, we studied the long-term efficacy of an HIV-based lentiviral 
vector carrying the human G6PC cDNA on the development of the hepatic disease in a new 
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GSD1a mouse model, which exhibits G6Pase deficiency exclusively in the liver. 
Interestingly, the liver-specific G6pc deficient (L-G6pc-/-) mice show normal life expectancy 
and manifest all hepatic symptoms of human GSD1a pathology, including the late 
development of HCA (32). This allowed us to study the effect of the treatment on tumour 
development.   
 
RESULTS 
Correction of fasted blood glucose and hypertriglyceridemia after lentiviral gene therapy in 
L-G6pc-/- mice 
To examine the efficacy of a lentiviral gene therapy in L-G6pc-/- mice, we developed an HIV-
based lentiviral vector expressing the human G6PC cDNA under the control of a liver-
specific murine transthyretin (mTTR) promoter (Fig. S1). The HIV-mTTR-hG6PC virus 
[4X107 to 10X107 transducing units] was injected in B6.G6pcex3lox/ex3lox.SAcreERT2/w neonates 
and the G6pc deletion was induced by tamoxifen treatment at weaning (Fig. S2). The HIV-
mTTR-GFP virus [encoded GFP] was injected as control. As previously described, L-G6pc-/- 
mice showed hypoglycaemia after 6h of fasting (Fig. 1A) (32). Indeed, blood glucose 
remained low in untreated L-G6pc-/- mice after 6h of fasting, reaching about 50-60 mg/dL 
compared to 140-150 mg/dL in WT mice (Fig. 1A). On the contrary, blood glucose reached 
normal levels in HIV-G6PC treated L-G6pc-/- mice from 2 months after G6pc deletion and 
throughout the course of the study, i.e. until 9 months (Fig. 1A). Concomitantly, biochemical 
analyses revealed that plasma TG were restored in lentivirus-treated mice (Fig. 1B). However, 
hypercholesterolemia was not corrected by gene therapy (Fig. 1C).  
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Prevention of hepatic GSD1a pathology using lentiviral gene therapy  
Usually the hepatomegaly is the first symptom detected in GSD1a. It is caused by a massive 
G6P accumulation, leading to excessive glycogen stores. Moreover, the hepatic G6PC 
deficiency leads to TG accumulation in the hepatocytes, resulting in hepatic steatosis. As 
previously described (32), L-G6pc-/- mice showed enlarged livers associated with 
accumulation of G6P, glycogen and TG (Fig. 2). Interestingly, hepatomegaly was partially 
prevented in lentivirus-treated L-G6pc-/- mice (the liver accounted for 5.6±0.1% of total body 
mass) compared to untreated L-G6pc-/- mice (the liver accounted for 9.4±0.6% of total body 
mass), without being normalized compared to WT mice (the liver accounted for 4.2±0.1% of 
total body mass) (Fig. 2A). This was associated with a substantial decrease in hepatic G6P 
overload (1.6±0.1 µmol G6P/g of liver in lentivirus-treated compared to 4.0±0.3 µmol G6P/g 
of liver in untreated L-G6pc-/- mice) (Fig. 2B). Moreover, lentivirus-treated L-G6pc-/- mice 
presented a decrease in hepatic glycogen content after 9 months of gene therapy (46.3±2.6 mg 
glycogen/g of liver) compared to untreated L-G6pc-/- mice (69.8±4.8 mg glycogen/g of liver) 
(Fig. 2C). Interestingly, hepatic steatosis was substantially prevented by lentiviral gene 
therapy since hepatic TG content of lentivirus-treated L-G6pc-/- mice was lower than that of 
untreated L-G6pc-/- mice and not significantly different as that of the WT mice (Fig. 2D). 
Histological observations of the livers of untreated L-G6pc-/- mice conﬁrmed a marked 
steatosis, with an enlargement of hepatocytes containing large lipid vacuoles, mainly in the 
periportal areas (Fig. 3A, panel b). Lentivirus-treated L-G6pc-/- mice exhibited large areas 
showing normal appearance of hepatocytes. However, some areas with enlarged hepatocytes 
were still observed (Fig. 3A, panel c). Moreover, serial section analyses performed in the liver 
of lentivirus-treated L-G6pc-/- mice revealed that hepatocytes expressing G6PC, detected by 
immunohistochemistry (Fig. 3B panels b), presented a normal morphology with an absence of 
lipid vacuoles (Fig. 3B, panels a). On the contrary, the areas with steatosis matched perfectly 
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with G6pc-/-hepatocytes, which did not express G6PC (Fig. 3B). To confirm that hepatocytes 
expressing G6PC were corrected cells, we analysed the expression of human G6pc mRNA in 
the lentivirus-treated liver compared to that of the mouse G6pc mRNA of WT liver. As 
expected, the human G6pc mRNA was undetectable in untreated mice and was substantially 
expressed in lentivirus-treated mice. Quantitatively, its expression was 10 fold lower than that 
of endogenous mouse G6pc mRNA in the WT liver (Fig. 3C). It may be noted that the 
transcription of a truncated mouse G6pc mRNA mRNA (containing exon 1 and 2) was up 
regulated in L-G6pc-/- liver, as previously reported (32). Consistent with a decrease in 
glycogen stores and normalization of hepatic TG levels, none of the HIV-G6PC treated L-
G6pc-/- mice (total of 11) developed hepatic tumours, as observed by MRI analysis after 9 
months of gene therapy. On the contrary, most untreated L-G6pc-/- mice (17 out of 24) had 
multiple millimetric hepatic lesions (1 to 4 mm of diameter) at the end of the experiment (Fig. 
4A-B). Almost all lesions corresponded to HCA (Fig. 4C and E), with the exception of one 
found in an untreated L-G6pc-/- mouse, which developed an HCC (Fig. 4D and F).  
Mosaic restoration of G6PC in L-G6pc-/- livers after gene therapy 
As previously observed, G6Pase was mainly expressed in the periportal area compared 
to the perivenous area of the liver in the WT mice (Fig. 5A, panels a-b). In agreement with the 
deletion of G6pc, G6PC protein was undetectable by immunohistochemistry in untreated L-
G6pc-/-mice (Fig. 5A panels c-d). Interestingly, G6PC was specifically localized in 
hepatocytes found in the close vicinity of blood vessels after 6 weeks post-injection in 
lentivirus-treated L-G6pc-/- mice; these hepatocytes exhibited high immunostaining for G6PC 
whereas a substantial proportion of the surrounding hepatocytes were G6PC-negative (Fig. 
5A panels e-f). After 9 months of gene therapy, lentivirus-treated L-G6pc-/- hepatocytes 
presented a patchy localization of the G6PC protein, in both the periportal and perivenous 
areas (Fig. 5A panels g-h). Thus immunostaining of G6PC was observed in large and diffuse 
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areas around vessels. The presence of large and diffuse G6PC positive areas around vessels 9 
months after the lentiviral gene therapy was probably due to hepatocyte divisions. Indeed, 
lentivirus-treated L-G6pc-/- mice exhibited an increased number in transduced hepatocytes, 
from 8 ± 3.5% at 6 weeks to 18 ± 0.9 at 9 months after hepatocyte transduction (Fig. 5B). 
Moreover, the G6Pase activity in the liver represented about 25% of WT hepatic G6Pase 
activity at 9 months post-injection, respectively (Fig.  5C). Finally, it is noteworthy that the 
DNA transgene was detected in several tissues after lentiviral gene therapy because the viral 
vectors were injected into the bloodstream (Fig. 5D). Nine months after gene therapy, the 
viral vector copy numbers were determined in the livers of lentivirus-treated mice by qPCR 
and found to represent about 3 copies per 100 cells. As expected, the human G6PC transgene 
was mainly expressed in the liver, although we observed a small leak in the spleen (data not 
shown). 
 
DISCUSSION 
Since the 1980s, dietary management to achieve suitable metabolic control has 
considerably improved the life expectancy of GSD1 patients, but various complications occur 
with aging. One of the main causes of morbidity and mortality in aging GSD1 patients derives 
from the development of HCA. Most patients develop many HCAs, which can grow, become 
haemorrhagic or malignant over time (10–12). In this context, liver gene therapy provides an 
attractive alternative to liver transplantation, which is currently the only effective therapy 
performed on the basis of serious impairment of metabolic control or risk of malignant 
transformation. To date, the most promising gene therapy approaches to treat GSD1a were 
focused on the use of AAV in order to achieve efficient in vivo gene transfer in the liver (17, 
18). However, AAV vectors rarely integrate into the host genome, remaining primarily in an 
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episomal form, and thus providing prolonged transgene expression only in the absence of cell 
division (33). Even after delivery in adult mice, a gradual loss of the transgene expression and 
of the therapeutic effect may be expected because of the turner-over (even low) of 
hepatocytes (34, 35). In addition, because of some cross-reactivity of neutralizing antibodies 
across AAV serotypes, the re-injection of a second AAV different from the first one may be 
inefficient. In contrast to AAVs, lentiviral vectors efficiently integrate into the cellular 
genome, providing long-term expression, in both quiescent cells and cells that are actively 
dividing (24). However, it appeared that lentiviral vectors transduce less efficiently the cells 
that are in the G0 state of the cell cycle, such as differentiated adult hepatocytes (14, 24, 36). 
Moreover, an immune response to the therapeutic protein could also preclude the long-term 
correction of the disease (24). New strategies have been devised to prevent the expression of 
the transgene in antigen-presenting cells and thus to bypass the immune response (24). It must 
be mentioned that a previous study using a feline lentivirus expressing the human G6PC 
cDNA was performed at a neonatal stage, to avoid an immune response against the transgene 
components (37). This allowed the authors to normalize blood glucose and to attenuate the 
hepatic disease (i.e. a decrease in glycogen accumulation) in the total knockdown G6pc 
mouse after a double neonatal virus administration. Here we report the use of a similar 
recombinant vector, i.e. an HIV-based lentiviral vector carrying the human G6PC cDNA 
under the liver-specific mTTR promoter. It is noteworthy that this study was performed in 
L.G6pc-/- mice exhibiting a long life expectancy that allowed us to study the effect of the 
lentiviral treatment on tumour development, a question not addressed in the former study. 
Interestingly, the HCA development seems to be accelerated in mice treated with tamoxifen at 
the age of 3 weeks, compared with mice treated at adult age (6-8 weeks). Indeed, small 
hepatic nodules of about 3-4 mm in diameter were detected in most untreated L.G6pc-/- mice 
after 9 months of G6pc deletion, whereas only 20-30% L.G6pc-/- mice showed millimetric 
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nodules when G6pc deletion was performed in adults (32). In our study, lentiviral gene 
therapy restored about 25% of basal hepatic G6Pase activity that enabled the treated L-G6pc-/- 
mice to maintain normal fasting blood glucose levels and to normalize hypertriglyceridemia 
for 9 months. Moreover, lentivirus-treated L.G6pc-/- mice presented a decrease in hepatic 
glycogen stores and a normalization of TG contents, at 9 months after gene therapy. In 
addition, lentivirus-treated mice did not show hepatic lesions after 9 months while most of 
untreated L-G6pc-/- mice developed HCA at this time. It is noteworthy that a recent study 
reported the prevention of HCA in the total G6pc KO mice treated by an AAV approach, 
despite hepatomegaly and elevated hepatic glycogen stores (19). However, the AAV-treated 
G6pc KO mice exhibited no steatosis and had normal levels of hepatic TG (19). Taken 
together with the study here, these data suggest that the excessive lipid accumulation rather 
than the glycogen accumulation could be the cause of the long-term consequence of HCA 
developed in L-G6pc-/- mice. Interestingly, many evidence suggest that nonalcoholic fatty 
liver disease, which is characterized by hepatic steatosis, is associated with the development 
of hepatic tumours, without overt hepatic fibrosis or cirrhosis (38, 39). Some hypothetical 
mechanisms include oxidative stress, adipocytokine functional disorder, or chronic 
inflammation linked to lipotoxicity (40). Further studies should be conducted to highlight the 
central role of fatty liver in tumour development. In our study, the prevention of HCA 
formation with lentiviral gene therapy is associated with the presence of large and diffuse 
areas expressing G6PC, representing about 20% of the liver surface (see Fig. 5A panels g-h 
and 5B). This is probably due to the transgene integration into the host genome and 
transmission during hepatocyte divisions in the neonatal liver. The clonal expansion of 
transduced cells could be explained by a selective advantage to treated cells. However, long-
term studies will be required to know whether the liver GSD1a disease is only improved for a 
while or whether it is cured definitely.  Indeed, the rescue of a partial G6Pase activity in a low 
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proportion of hepatocytes could only permit to maintain blood glucose level and will not cure 
the rest of hepatocytes, which will still be prone to hepatic tumour development with time. 
Contrarily to monogenic diseases that involve a primary defect in a hepatic protein without 
significant parenchymal damage and hepatic injury, such as Crigler-Najjar disease or 
coagulation defects, gene therapy approach of GSD1a has to correct a maximum of G6pc-/- 
hepatocytes in order to prevent at best the development of the hepatic disease. Contrarily, 
Crigler-Najjar disease or coagulation defects only require the expression of only low levels of 
the related hepatic protein in the blood stream to treat or prevent the systemic illness 
manifestations.  
Finally, in comparison to gamma retroviral LTR-driven vectors, lentiviral vectors 
present with favourable features like a potentially safer insertion profile. Thus our study 
supports the absence of genotoxicity of HIV1-derived lentiviral vectors in the liver (23, 25). 
However, the residual genotoxicity risk associated with the preferential intragenic integration 
events represents the most obvious concern. The substantial flexibility of the lentiviral vector 
genome offers opportunities for redesigning sequences of the backbone as well as the 
therapeutic cargo to further reduce this risk.  
In conclusion, we demonstrate here that the lentiviral gene therapy performed during the 
neonate period permits a strong expression of G6Pase, corrects fasting blood glucose levels 
and prevents the hepatic disease, including the HCA formation, for at least 9 months in L-
G6pc-/- mice. However, more efficient approaches are still needed to improve all parameters, 
including glycogen stores. A specific and stronger hepatic expression of the transgene could 
be obtained by adding regulatory sequences to the mTTR promoter (30, 41, 42). Moreover, 
since the mTTR promoter is leaky permitting a weak expression in non-liver cells, in 
particular in antigen presenting cells, the addition of mir142-3pT sequence in the vector 
backbone would be useful to prevent an immune rejection of transduced cells (27, 43). In 
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addition, it is interesting to note that the lentiviral vector gene therapy permits the 
transduction of the three organs affected by GSD1a, i.e. the liver, kidney and intestine (see 
Fig.5D). This indicates that this approach might be suitable as a possible treatment of the 
kidney or intestine diseases if combined with the use of an appropriate promoter. Because a 
neonatal intervention in a clinical setting may drastically improve the phenotype in the most 
critical years of an infant development, the lentiviral gene therapy appears as an attractive 
approach for GSD1a treatment.  
 
MATERIALS AND METHODS 
Preparation of recombinant vectors encoding human G6PC  
We produced an HIV-based lentiviral vector carrying the human G6PC cDNA (or the GFP 
cDNA as control) under the control of the murine transthyretin (mTTR) promoter, fused to a 
synthetic hepatocyte-specific enhancer that specifically directs transcription to the liver (28), 
that specifically directs transcription to the liver. High-titre lentiviral vector stocks were 
generated as previously described by calcium phosphate-mediated transient transfection of 
three plasmids: the transfer vector plasmid, the packaging plasmid psPAX2, and the vesicular 
stomatitis virus G protein (VSV G) envelope protein-coding plasmid pMD2G (44). These 
self-inactivating transfer vectors harboured the cis-acting cPPT/CTS from HIV-1, which 
facilitates the nuclear translocation of preintegrative vector complexes (45, 46) and the 
posttranscriptional regulatory element from the woodchuck hepatitis virus, which increase 
transgene expression (47) and was inserted downstream of the transgene (Fig. S1). The titres 
of the viral preparations were determined as previously described (28) and were in the range 
of 1-2 x109 transducing units/mL. 
AAV and lentiviral vector administration into mice 
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Two-day old B6.G6pcex3lox/ex3lox.SAcreERT2/w mice were infused via the temporal vein with 50 
µL of HIV-mTTR-hG6PC virus (n= 11) or HIV-mTTR-hGFP virus containing 4X107 to 
10X107 transducing units in phosphate-buffered saline. Mice of the untreated group (n=24) 
corresponded to HIV-mTTR-hGFP injected mice.  
Generation of liver-specific G6pc knock-out mice 
The deficiency in G6Pase was obtained by a specific deletion of G6pc exon 3 in the liver, 
using a CRE-lox strategy (32). B6.G6pcex3lox/ex3lox.SAcreERT2/w and C57Bl/6J mice (Charles 
Rivers Laboratories, L’Arbresle, France) of both genders were injected intraperitoneally at 
15-21 day old with 0.5 mg of tamoxifen every day for four consecutive days, in order to 
obtain L-G6pc-/- and wild-type (WT) mice, respectively. Mice were housed in the animal 
facility of Lyon 1 University under temperature controlled (22°C) conditions and with a 12/12 
h light/dark cycle. Mice had free access to water and standard chow diet. Fasted mice were 
provided with continuous access to water. All the procedures were performed in accordance 
with the principles and guidelines established by the European Convention for the Protection 
of Laboratory Animals. The animal care committee of University Lyon 1 approved all the 
experiments.  
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) examinations were performed 5, 7 and 9 months after 
G6pc deletion on anesthetized mice on an horizontal 4.7T Biospec system (Bruker, Ettlingen, 
Germany) (32). T2-weighted contrast images were acquired in the axial plane with a fat 
suppressed rapid acquisition with relaxation enhanced (RARE) sequence with the following 
parameters: repetition time > 6 sec; 38.2 ms echo time; 30 x 30 mm2 Field of View, 256 x 192 
matrix, 32 slices of 0.7 mm thick; RARE factor = 4; 2 averages; 98 Hz of pixel bandwidth. A 
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trained radiologist who has over twenty years of experience analysed the MR images to detect 
nodules in vivo. 
Biochemical assays 
Blood glucose was followed after 6 h of fasting with an Accu-Chek Go glucometer (Roche 
Diagnostics, Meylan, France). Blood was withdrawn by submandibular bleeding using a 
lancet and collected into EDTA. Plasma triglycerides and cholesterol were determined with 
Biomérieux colorimetric kits (Marcy l’Etoile, France). Mice were killed by cervical 
dislocation. The liver was immediately removed, weighed and snap-frozen using tongs 
previously chilled in liquid N2 and stored at -80°C. All tissues were analysed macroscopically. 
Hepatic glycogen determinations were carried out on frozen tissue homogenates according to 
the procedure previously described (48). Total hepatic lipids were extracted by the method of 
Bligh and Dyer (49), and triglyceride content was measured using a Biomérieux colorimetric 
kit. Hepatic G6Pase activity was assayed at maximal velocity (20 mmol/l of G6P) at 30°C, as 
previously described (50). 
Gene expression 
Total RNAs were extracted from livers with TRIzol reagent (InVitrogen life technology, St 
Aubin, France), according to the manufacturer’s instructions. Reverse transcription was 
performed using the kit QuantiTect Reverse transcription (Quiagen France, Courtabeuf). 
Quantitative PCR was performed using the Advanced Universal SYBR Green Supermix (Bio-
Rad Laboratories, Marnes-la-Coquette) in the CFX Manager Realplex (Bio-Rad). Endogenous 
G6pc exon 1-exon 3 mRNA fragment was amplified using exon 1 mG6pc sense 
5’TTACCAAGACTCCCAGGACTG3’ and exon 2 mG6pc antisense 
5’GAGCTGTTGCTGTAGTAGTCG3’. The specific human G6PC exon 4-exon 5 mRNA 
fragment was amplified using exon 2 mG6pc sense 5’AGCGTCCATACTGGTGGGTTT3’ 
	 15	
and exon 3 mG6pc antisense 5’GGTCGGCTTTATCTTTCCCTG3’. The mouse ribosomal 
protein L19 transcript (Rpl19) was used as housekeeping gene (32). Calculations were based 
on the comparative cycle threshold method (2-ΔΔCt).  
Histological analysis 
A piece of the liver and hepatic nodules were fixed in 10% formalin for histological analyses 
and embedded in paraffin. Serial sections (4 µm thick) were cut and stained with hematoxylin 
and eosin (H&E) staining. Immunohistochemical analyses were performed as previously 
described, using a purified rabbit anti-G6PC antibody (dilution 1:1,000) (51). The slides were 
examined under a Coolscope microscope (Nikon Instruments, New York, US). The G6PC-
positive cell index was calculated and expressed as the percentage of positive stained area 
against total analysed area.  
The following criteria were used to identify HCA and HCC. HCA were defined as nodules, 
visible at macroscopic examination, well circumscribed, expansive, compressing the adjacent 
parenchyma. They were made of well-differentiated hepatocytes, usually larger than normal 
hepatocytes, with low nuclear-cytoplasmic ratio, eosinophilic, clear or vacuolated cytoplasm, 
and enlarged nuclei with well visible nucleoli. The normal trabecular architecture was 
retained; plates were regular and 1 to 2 cells thick. No connective septa were present. Mitotic 
figures were rare. In some cases, smaller basophilic, proliferative hepatocytes could be 
observed, usually at the periphery of the nodule; cell atypia might be present but only focally; 
no evidence of local tissue invasion or angioinvasion was detected. HCC was defined by the 
presence of architectural and cellular atypia. The architecture was mainly trabecular but plates 
were irregular, usually 2 to 4-cell thick branched and separated by dilated and capillarized 
sinusoidal vessels. Hepatocytes were of variable size, but were frequently characterized by 
low nuclear-cytoplasmic ratio and basophilic cytoplasm. Nuclear atypia was frequent. Mitoses 
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were numerous. Connective septa could be present. Tissue invasion and/or angioinvasion 
might be detected.  
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LEGENDS TO FIGURES 
Fig. 1: Plasma parameter following during 9 months after lentiviral gene therapy. 
(A) Blood glucose after 6h of fasting following during 9 months after gene deletion in WT 
(black squares), untreated L-G6pc-/- (white squares), and HIV-G6PC treated L-G6pc-/- mice 
(dark grey squares). Blood triglycerides (B) and total cholesterol (C) analysis after 6h of 
fasting at 1, 3, 6 and 9 months after tamoxifen treatment, in WT (black bars), untreated L-
G6pc-/- (white bars) and HIV-G6PC treated L-G6pc-/- mice (dark grey bars). The results are 
expressed as the mean ± SEM (n = 5 mice per group). The various groups were compared by 
one-way ANOVA followed by Tukey’s post-hoc test. Values significantly different from WT 
mice (p<0.05*, p<0.01** and p<0.001***) and from untreated L-G6pc-/- mice (p<0.05$, 
p<0.01$$ and p<0.001$$$) are indicated. 
 
Fig. 2: Analysis of hepatic parameters after lentiviral gene therapy 
(A) Liver weight compared to the body weight, (B) hepatic glucose-6-phosphate (G6P) 
content (C) hepatic glycogen content and (D) hepatic triglyceride content in WT (black bars), 
untreated L-G6pc-/- (white bars), and HIV-G6PC treated L-G6pc-/- mice (dark grey bars). Data 
were obtained at 9 months after G6pc deletion from mice fasted for 6h. The results are 
expressed as the mean ± SEM (n = 5 mice per group). The various groups were compared by 
one-way ANOVA followed by Tukey’s post-hoc test. Values significantly different from WT 
mice (p<0.01** and p<0.001***) and from untreated L-G6pc-/- mice (p<0.05$ and p<0.001$$$) 
are indicated. 
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Fig. 3: Histological analysis of the liver after lentiviral gene therapy 
(A) H&E section staining from the WT (a), untreated L-G6pc-/- (b), and HIV-G6PC treated L-
G6pc-/-mouse (c) livers. PP corresponds to the periportal area and PV to the perivenous 
region. (B) H&E staining (panel a) and immunohistochemical staining of G6PC (panel b) 
from serial sections of HIV-G6PC treated L-G6pc-/- livers after 9 months of G6pc deletion. 
(C) Quantification of the human and mouse G6pc mRNA expression in the livers of untreated 
or HIV-G6PC treated WT or L-G6pc-/- mice after 9 months of G6pc deletion. G6pc mRNA 
levels were expressed relatively to mL19 transcript. The asterisks correspond to undetectable 
value.  
 
Fig. 4: Tumour development in L-G6pc-/- mice 
(A-B) Liver resection after 9 months of hepatic G6pc deletion. Arrows point nodules of about 
3-4 mm of diameter. (C-F) Histological analysis by H&E staining of an HCA (C and E) and 
an HCC (D and F) developed in untreated L-G6pc-/- mice. Panels E and F correspond to a 
higher magnification of the tumours observed in panels C and D, respectively. 
 
Fig. 5: HIV-G6PC vector transduction, dissemination and expression.  
(A) Immunohistochemical analyses of G6PC in the liver of WT (a-b), untreated L-G6pc-/- (c-
d) and HIV-G6PC treated L-G6pc-/- after 6 weeks (e-f) or 9 months of lentiviral transduction 
(g-h) mice. Panels b, d, f and h correspond to a higher magnification of the G6PC positive 
areas observed in panels a, c, e and g, respectively. PP corresponds to the periportal area and 
PV to the perivenous region. (B) Computerized quantification of G6PC positive hepatocytes 
detected by immunohistochemistry in the liver of HIV-G6PC treated mice at 6 weeks (dark 
grey bar) or 9 months (light grey bars) of lentiviral transduction. (C) G6Pase activity in the 
liver of WT (black bars), untreated L-G6pc-/- (white bars) and HIV-G6PC treated mice at 9 
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months of lentiviral transduction (light grey bars). (D) Determination of vector dissemination 
by PCR. Genomic DNA was extracted from various organs of HIV-G6PC treated L-G6pc-/- 
mice. The presence of human G6PC cDNA was detected by PCR. As a control, a fragment 
from the murine G6pc gene was also amplified. The results are expressed as the mean ± SEM 
(n = 5 mice per group). The various groups were compared by one-way ANOVA, followed by 
Tukey’s post-hoc test for (B) and by an unpaired two-tailed Student’s t-test (C). Values 
significantly different from WT mice (p<0.001***) and from untreated L-G6pc-/- mice 
(p<0.001$$$) are indicated. 
 
List of abbreviations: AAV, Adeno-associated virus; BM, Body Mass; G6P, glucose-6 
phosphate; G6Pase, glucose-6 phosphatase; GSD1, glycogen storage disease type 1; HCA, 
hepatocellular adenoma; HCC, hepatocellular carcinoma; HIV, human immunodeficiency 
virus; mTTR, murine transthyretin; TG, triglycerides; WT, wild type. 
 





